N@N

Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900

Jim Cramer, a prominent financial commentator, has expressed a strong preference for Eli Lilly (LLY) over Regeneron Pharmaceuticals, even if Eli Lilly's stock price were to reach $900 per share. In his analysis, Cramer highlights Eli Lilly's robust pipeline and its potential in the obesity and diabetes markets, particularly with drugs like Mounjaro, which has shown promising results. He contrasts this with Regeneron, noting that while it has successful products like Eylea for eye diseases, its future growth might not match Eli Lilly's due to less diversified and less expansive upcoming treatments. Cramer's endorsement of Eli Lilly is based on its innovation, market positioning, and the significant impact its new drugs could have on its revenue and stock performance.

Read the Full Insider Monkey Article at:
[ https://www.insidermonkey.com/blog/jim-cramer-says-he-would-prefer-eli-lilly-lly-over-regeneron-even-at-900-1405891/ ]